

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner



Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

DUR COMMITTEE AGENDA

Date: Tuesday, December 8, 2020
Time: 6:00PM to 8:30PM
Location: Virtual: Join Zoom Meeting
<https://us02web.zoom.us/j/83746725612?pwd=SDVwbE0wUjB1bFo2VmR4dTlZSGdpZz09>
Meeting ID: 837 4672 5612
Passcode: zmHN9D

- 1) Closed Session: 5:30PM- 6:00PM- Board members only (a separate invitation to be sent)
- 2) MaineCare Updates
- 3) Public Comments
- 4) Old Business
 - Approve October Meeting Minutes
- 5) Revised clinical criteria
 - None at this time
- 6) New Business (open session)
 - Retro DUR
 - Introduce: Influenza Vaccination Rates
 - Data Presentation: Chantix Use
 - New Drug Review (<http://www.mainearepd.org/>)

AirDuo Digihaler (antiasthmatic - adrenergic combinations)
Alkindi (glucocorticoids/ mineralocorticoids)
Armonair Digihaler (antiasthmatic - steroid inhalants)
Bafiertam (multiple sclerosis - non-interferons)
Blenrep (cancer)
Breztri (antiasthmatic - adrenergic combinations)
Cystadrops (ophthalmic)
Cystaran (ophthalmic)
Dojolvi (electrolytes/ nutritional)
Enspryng (monoclonal antibody)
Evrysdi (neurologics- SMA)
Gavreto (cancer)
Hemady (glucocorticoids/ mineralocorticoids)

Inqovi (cancer)
Kesimpta (multiple sclerosis - non-interferons)
Lampit (antiprotozoals)
Licart (NSAIDS)
Mycapssa (somatostatic agents)
Ongentys (parkinsons - COMT inhibitors)
Onureg (cancer)
Polivy (cancer)
Tecartus (cancer)
Uplizna (monoclonal antibody)
Viltepso (muscular dystrophy agents)
Xywav (stimulant - stimulant like)

7) FDA Safety Alerts

CDER proposes withdrawal of approval for Makena

https://www.fda.gov/drugs/drug-safety-and-availability/cder-proposes-withdrawal-approval-makena?utm_medium=email&utm_source=govdelivery

FDA advises health care professionals and patients about insulin pen packaging and dispensing

https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-health-care-professionals-and-patients-about-insulin-pen-packaging-and-dispensing?utm_medium=email&utm_source=govdelivery

FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications

https://www.fda.gov/news-events/press-announcements/fda-warns-using-type-pain-and-fever-medication-second-half-pregnancy-could-lead-complications?utm_medium=email&utm_source=govdelivery

- 8) Next Meeting (Tuesday, March 9, 2021 (from 5:30pm to 8:30pm)
- 9) Adjournment: 8:30PM